Chronic Lymphocytic Leukemia

The effects observed with concurrent ibrutinib and lisocabtagene maraleucel in the relapsed or refractory chronic lymphocytic leukeima population included changes in gene signatures related to proliferation, inflammation, and T cell exhaustion.

With standard BTK inhibitor therapy, deep responses are rare for patients with chronic lymphocytic leukemia. A novel agent, TG-1701 is showing promise.

Optical genome mapping may help to detect genetic abnormalities in patients with CLL.

During a live virtual event, Sameer A. Parikh, MBBS, discussed with participating physicians frontline treatment options in patients with chronic lymphocytic leukemia.

In patients with CLL who were treated with venetoclax, acalabrutinib, and obinutuzumab, Cell-free DNA–based minimal residual disease testing was found to be feasible.

Long-lasting responses to the triplet combination of umbralisib, ublituximab, and pembrolizumab were seen in a phase 1/2 study.

Patients treated with acalabrutinib monotherapy had a significantly longer mean duration of time spent without toxicity compared with those treated with chlorambucil plus obinutuzumab in the phase 3 ELEVATE-TN trial.

During a live virtual event, Sameer A. Parikh, MBBS, discussed with participating physicians frontline treatment options of BTK inhibitors in patients with chronic lymphocytic leukemia.

Catherine Callaghan Coombs, MD, discusses the mechanism of action of pirtobrutinib in chronic lymphocytic leukemia and small lymphocytic leukemia.

Catherine Callaghan Coombs, MD, discusses 2 upcoming trials in chronic lymphocytic leukemia.

During a live virtual event, Sameer A. Parikh, MBBS, discussed with participating physicians the treatment options for patients with chronic lymphocytic leukemia in the front-line setting by risk assessment.

In a phase 1 dose-escalation study, an investigational BTK degrader showed clinically meaningful results in patients with chronic lymphocytic leukemia and elicited a response.

Mazyar Shadman, MD, MPH, and Jonathon Cohen, MD, MS, discuss possible future developments with BTKi as therapy options in B-cell lymphomas.

Drs Shadman and Cohen introduce new data concerning a third-generation BTK inhibitor, pirtobrutinib, and discuss unmet needs in the B-cell malignancy landscape.

Good activity was seen with acalabrutinib in combination with venetoclax and obinutuzumab in the front-line setting for select patients with chronic lymphocytic leukemia.

Mazyar Shadman, MD, MPH, and Jonathon Cohen, MD, MS, share their preferences regarding BTK-targeted treatment in B-cell malignancies.

Two experts discuss use of ibrutinib and zanubrutinib and data from the ALPINE and ELEVATE-RR trials.

In chronic lymphocytic leukemia management, many patients do not fall within the category to receive chemoimmunotherapy. However, for high-risk patients, targeted agents are changing the treatment landscape.

The future of minimal residual disease testing in chronic lymphocytic leukemia may be applicable for patients being treated with venetoclax in combination with Bruton’s tyrosine kinase inhibitors.

LAVA-051 for the treatment of CLL was granted an orphan drug designation by the FDA. Results of a phase 1 study of the agent are expected in the first half of 2022.

Drs Shadman and Cohen review clinical trials of zanubrutinib in B-cell lymphomas.

Mazyar Shadman, MD, MPH, and Jonathon Cohen, MD, MS, talk about disease progression on BTKi and what mechanisms of resistance can occur.

Catherine Callaghan Coombs, MD, discusses the results of the phase 1/2 BRUIN study of pirtobrutinib in chronic lymphocytic leukemia and small lymphocytic leukemia.

The ASSURE trial is actively recruiting patients with chronic lymphocytic leukemia to receive acalabrutinib in an investigation of its safety and efficacy.

IGHV and TP53 remain clinical prognostic importance in patients with chronic lymphocytic leukemia, despite many prognostic markers for chemoimmunotherapy losing their clinically relevance in the context of targeted therapies for patients.